Trium Capital’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Trium Capital’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-117,456	Closed	-$312K	–	104
2024 Q1	$312K	Buy	+117,456	New	+$291K	0.12%	60

Trium Capital's KNTE Position: Q2 2024 in Review

Trium Capital sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 117,456 shares — an estimated $312K sold.

Trium Capital first reported a position in KNTE in Q1 2024 and held it in 1 quarter. The position peaked at $312K in Q1 2024. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

Trium Capital reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Trium Capital sold 117,456 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $312K.
Trium Capital first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2024 and held it in 1 quarter.
Trium Capital's Kinnate Biopharma Inc. Common Stock position peaked at $312K in Q1 2024.
0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Trium Capital's 13F filing for Q2 2024, filed 6 Aug 2024.